Program
Methylprednisolone
Also written as “methylprednisolone”, “Vasopressin; Methylprednisolone; Hydrocortisone” and “Methylprednisolone/prednisolone”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Myeloma · Diabetes Insipidus · Myopathies, Structural, Congenital · Gaucher Disease, led by 9 companies.
Drug pageMethylprednisolone: every studyMany companies study it; this page follows only the 16 they lead. All 405 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 40 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Dec 13, 2010 | Dec 13, 2010 | none ahead |
| Oncotherapeuticsits history only | 22 open or running | phase 1since Nov 7, 2023 | Nov 7, 2023 | Apr 1, 2027phase 1 · NCT06225310 |
| Amsterdam Molecular Therapeuticsits history only | 10 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| Astellas Pharmaits history only | 11 open or running | phase 2since Jun 30, 2025 | Jun 30, 2025 | Oct 31, 2027phase 2 · NCT07052929 |
| Bristol-Myers Squibbits history only | 10 open or running | phase 2since May 4, 2016 | May 4, 2016 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eli Lillyits history only | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 2since Oct 31, 2016 | Oct 31, 2016 | none ahead |
Also a collaborator on its studies: Incyte, Elan Pharmaceuticals and The Clinical Trial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2005First study: phase 4 study in Multiple Sclerosis, Relapsing-RemittingNew to BiogenBiogen · NCT00112034 · 350 enrolled · United States
- Jun 25, 20072 phase 4 studies in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT00493116, NCT00492466
- Apr 30, 2009Amsterdam Molecular Therapeutics’ first study: phase 3 study in Hyperlipoproteinemia Type INew to Amsterdam Molecular TherapeuticsAmsterdam Molecular Therapeutics · NCT00891306 · 5 enrolled · Canada
- Feb 17, 2010Phase 2 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT01071083 · 175 enrolled · United States, Germany, Spain
- Dec 13, 2010Pfizer’s first study: phase 1 study in Biological AvailabilityNew to PfizerPfizer · NCT01267201 · 24 enrolled · Singapore
- Jul 25, 20113 phase 1 studiesPfizer · NCT01405170, NCT01405157, NCT01405131
- May 4, 2016Bristol-Myers Squibb’s first study: phase 2 study in Carcinoma, Renal CellNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02763761 · United States
- Oct 31, 2016Sun Pharmaceutical Industries’ first study: phase 2 study in Prostatic NeoplasmsNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT02962284 · 20 enrolled
- Jan 3, 2019Chong Kun Dang Pharmaceutical’s first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
- May 11, 2020Eli Lilly’s first study: phase 2 study in Gaucher DiseaseNew to Eli LillyEli Lilly · NCT04411654 · 7 enrolled · United States, United Kingdom
- Nov 7, 2023Oncotherapeutics’ first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT06225310 · 30 planned · United States
- Jan 8, 2024Early phase 1 study in Multiple MyelomaOncotherapeutics · NCT06209606 · 30 planned · United States
- Jun 30, 2025Astellas Pharma’s first study: phase 2 study in Myopathies, Structural, CongenitalNew to Astellas PharmaAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
Ahead
- Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
- Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT06209606Multiple Myeloma · United States | Early 1 | Recruiting | Oncotherapeutics | May 2026 | 30 |
| NCT06225310Multiple Myeloma · United States | 1 | Recruiting | Oncotherapeutics | Apr 1, 2027 | 30 |
| NCT04411654Gaucher Disease · United States, United Kingdom | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 7 |
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 22, 2022 | 169 |
| NCT02962284Prostatic Neoplasms | 2 | Completed | Sun Pharmaceutical Industries | Mar 2018 | 20 |
| NCT02763761Carcinoma, Renal Cell · United States | 2 | Withdrawn | Bristol-Myers Squibb | Mar 31, 2017 | 0 |
| NCT01405170Lecithin Cholesterol Acyltransferase Deficiency | 1 | Withdrawn | Pfizer | Oct 28, 2011 | 0 |
| NCT01405157Fasting | 1 | Withdrawn | Pfizer | Feb 20, 2012 | 0 |
| NCT01405131Therapeutic Equivalency | 1 | Withdrawn | Pfizer | Feb 20, 2012 | 0 |
| NCT01267201Biological Availability · Singapore | 1 | Completed | Pfizer | Dec 2010 | 24 |
| NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain | 2 | Completed | Biogen | Nov 2011 | 175 |
| NCT00891306Hyperlipoproteinemia Type I · Canada | 3 | Completed | Amsterdam Molecular Therapeutics | Aug 2010 | 5 |
| NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand | 4 | Completed | Biogen | Dec 2009 | 20 |
| NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland | 4 | Completed | Biogen | Aug 2006 | 14 |
| NCT00112034Multiple Sclerosis, Relapsing-Remitting · United States | 4 | Completed | Biogen | Jun 2006 | 350 |
How it is read
Names in the registry
- “methylprednisolone”, 16 entries
- “Methylprednisolone”, 7 entries
- “Vasopressin; Methylprednisolone; Hydrocortisone”, 1 entry
- “Methylprednisolone/prednisolone”, 1 entry
- “abiraterone acetate with Methylprednisolone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 4 studies
- Multiple Myeloma, 2 studies
- Diabetes Insipidus, 1 study
- Myopathies, Structural, Congenital, 1 study
- Gaucher Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.